Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial

Author's Avatar
Jan 22, 2020
Article's Main Image

Analysis to adjust for significant baseline imbalance in Severe Impairment Battery scores between treatment groups shows improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, the primary endpoint

National Institute of Health awards $2.7 million grant to Neurotrope to conduct additional clinical research for patients with advanced Alzheimer's disease

Company continues to explore strategic alternatives

PR Newswire